Brought to you by 
AZ divests Nexium and Vimovo rights to Grunenthal
31 Oct 2018
Executive Summary
AstraZeneca PLC has divested some more non-core assets to Grunenthal GMBH, this time granting the company rights to its GERD therapy Nexium (esomoprezole) and arthritis product Vimovo (esomoprezole/naproxen).
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AZ divests Nexium and Vimovo rights to Grunenthal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice